Published : 21 Jul 2023

---

The end of July 2023 saw another reputed Global Pharma appoint Aagami for finding partner for ready to commercialize Denosumab Biosimilar in Japan.

The client leadership has known Aagami for a long time as Aagami has brought many of our opportunities to them. Having seen our work all these years, the client has entrusted Aagami to support them for Japan market, where Aagami has very good experience, network, and expertise, including Japanese language capabilities, and deep understanding of how the region works. 

Product (Denosumab Biosimilar) Highlights:

·       Superior quality and Significant cost advantage at commercial scale

·       Commercial supplies ongoing with several big pharma companies for client's Denosumab biosimilar in already commercialized regions as below.

·       Licensing Agreements established for the Osteoporosis indication [biosimilar to Prolia®] in EEA, UK, Australia, South Korea, Thailand, Brazil, Mexico, and Chile. 

·       Licensing open for Japan and other territories.

We at Aagami are excited to bring success to the client in Japan market by finding them a long-term suitable partner. 

If you would like to know more about this opportunity, please contact us.